300583 赛托生物
交易中 05-14 14:29:48
资讯
新帖
简况
赛托生物：公司暂无直接治疗汉坦病毒的抗病毒药物
证券之星 · 05-13 11:30
赛托生物：公司暂无直接治疗汉坦病毒的抗病毒药物
赛托生物（300583）披露回购公司股份进展公告，5月8日股价上涨1.76%
证券之星 · 05-08
赛托生物（300583）披露回购公司股份进展公告，5月8日股价上涨1.76%
每周股票复盘：赛托生物（300583）一季度净利增113.15%
证券之星 · 05-03
每周股票复盘：赛托生物（300583）一季度净利增113.15%
赛托生物（300583）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 04-29
赛托生物（300583）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
图解赛托生物年报：第四季度单季净利润同比增长96.21%
证券之星 · 04-28
图解赛托生物年报：第四季度单季净利润同比增长96.21%
赛托生物（300583）披露回购公司股份进展公告，4月7日股价上涨3.15%
证券之星 · 04-07
赛托生物（300583）披露回购公司股份进展公告，4月7日股价上涨3.15%
赛托生物(300583.SZ)：甲泼尼龙取得化学原料药欧洲CEP证书
智通财经 · 03-25
赛托生物(300583.SZ)：甲泼尼龙取得化学原料药欧洲CEP证书
赛托生物最新公告：子公司收到倍他米松化学原料药上市申请批准通知书
证券之星 · 03-16
赛托生物最新公告：子公司收到倍他米松化学原料药上市申请批准通知书
赛托生物(300583.SZ)子公司收到地塞米松化学原料药上市申请批准通知书
智通财经 · 03-13
赛托生物(300583.SZ)子公司收到地塞米松化学原料药上市申请批准通知书
赛托生物（300583）披露回购股份报告书，3月9日股价下跌0.14%
证券之星 · 03-09
赛托生物（300583）披露回购股份报告书，3月9日股价下跌0.14%
赛托生物(300583.SZ)拟斥1500万元至3000万元实施回购
智通财经 · 03-06
赛托生物(300583.SZ)拟斥1500万元至3000万元实施回购
赛托生物（300583）披露关于子公司收到化学原料药欧洲CEP证书的公告，2月24日股价上涨1.01%
证券之星 · 02-24
赛托生物（300583）披露关于子公司收到化学原料药欧洲CEP证书的公告，2月24日股价上涨1.01%
赛托生物(300583.SZ)取得倍他米松原料药CEP证书
智通财经网 · 02-13
赛托生物(300583.SZ)取得倍他米松原料药CEP证书
赛托生物（300583）披露控股子公司再次获得高新技术企业证书，2月6日股价上涨0.14%
证券之星 · 02-06
赛托生物（300583）披露控股子公司再次获得高新技术企业证书，2月6日股价上涨0.14%
股市必读：赛托生物（300583）预计2025年全年扣非后净利润亏损6600万元至9100万元
证券之星 · 02-02
股市必读：赛托生物（300583）预计2025年全年扣非后净利润亏损6600万元至9100万元
赛托生物（300583）披露2025年度业绩预告，1月30日股价上涨0.76%
证券之星 · 01-30
赛托生物（300583）披露2025年度业绩预告，1月30日股价上涨0.76%
股市必读：赛托生物（300583）1月26日董秘有最新回复
证券之星 · 01-27
股市必读：赛托生物（300583）1月26日董秘有最新回复
赛托生物最新公告：收到化学原料药欧洲CEP证书
证券之星 · 01-20
赛托生物最新公告：收到化学原料药欧洲CEP证书
赛托生物（300583）披露公司及子公司日常关联交易预计，1月16日股价下跌0.69%
证券之星 · 01-16
赛托生物（300583）披露公司及子公司日常关联交易预计，1月16日股价下跌0.69%
股市必读：赛托生物（300583）1月9日董秘有最新回复
证券之星 · 01-12
股市必读：赛托生物（300583）1月9日董秘有最新回复
加载更多
公司概况
公司名称：
山东赛托生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2017-01-06
主营业务：
山东赛托生物科技股份有限公司的主营业务是应用基因工程技术和微生物转化技术制造并销售甾体药物原料和中间体。公司的主要产品是甾体核心中间体、高端中间体、呼吸类高端特色原料药、动保类原料药、乳膏鼻喷制剂。
发行价格：
40.29
{"stockData":{"symbol":"300583","market":"SZ","secType":"STK","nameCN":"赛托生物","latestPrice":15.44,"timestamp":1778740188000,"preClose":15.41,"halted":0,"volume":2807793,"delay":0,"changeRate":0.0019,"floatShares":186000000,"shares":190000000,"eps":-0.2216,"marketStatus":"交易中","change":0.03,"latestTime":"05-14 14:29:48","open":15.43,"high":15.55,"low":15.27,"amount":43176600,"amplitude":0.0182,"askPrice":15.45,"askSize":35,"bidPrice":15.44,"bidSize":349,"shortable":0,"etf":0,"ttmEps":-0.2216,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778742000000},"marketStatusCode":2,"adr":0,"adjPreClose":15.41,"symbolType":"stock","openAndCloseTimeList":[[1778722200000,1778729400000],[1778734800000,1778742000000]],"highLimit":16.95,"lowLimit":13.87,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":189702126,"isCdr":false,"pbRate":1.66,"roa":"--","roe":"0.21%","epsLYR":-0.39,"committee":0.50096,"marketValue":2929000000,"turnoverRate":0.0151,"status":0,"floatMarketCap":2874000000},"requestUrl":"/m/hq/s/300583/","defaultTab":"news","newsList":[{"id":"2635273752","title":"赛托生物：公司暂无直接治疗汉坦病毒的抗病毒药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2635273752","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635273752?lang=zh_cn&edition=full","pubTime":"2026-05-13 11:30","pubTimestamp":1778643036,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物(300583)05月12日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司生产的原料药，很多呼吸系统疾病和流行性呼吸传染病药物都有用到；近期，国外已出现汉坦病毒病例，贵司生产的相关原料药，是否有机会应用于治疗汉坦病毒病例的机会?赛托生物回复：尊敬的投资者，您好！公司暂无直接治疗汉坦病毒的抗病毒药物，糖皮质激素药品一般在危重症患者、减轻炎症反应方面作为辅助治疗药物（以临床指导为准）。请您注意投资风险。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300017484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633434605","title":"赛托生物（300583）披露回购公司股份进展公告，5月8日股价上涨1.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633434605","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633434605?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:56","pubTimestamp":1778234185,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，赛托生物报收于15.57元，较前一交易日上涨1.76%，最新总市值为29.54亿元。该股当日开盘15.3元，最高15.68元，最低15.16元，成交额达7066.01万元，换手率为2.46%。赛托生物于2026年5月8日披露《关于回购公司股份的进展公告》。公告显示，公司于2026年3月6日召开第四届董事会第十三次会议，审议通过回购公司股份方案，拟使用自有资金和自筹资金以集中竞价交易方式回购股份，用于员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800032368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632670192","title":"每周股票复盘：赛托生物（300583）一季度净利增113.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632670192","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632670192?lang=zh_cn&edition=full","pubTime":"2026-05-03 07:07","pubTimestamp":1777763231,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，赛托生物报收于15.12元，较上周的13.79元上涨9.64%。本周，赛托生物4月30日盘中最高价报15.28元。本周关注点来自业绩披露要点：赛托生物2026年一季报显示，归母净利润361.66万元，同比上升113.15%。股本股东变化股东户数变动截至2026年3月31日，赛托生物股东户数为1.37万户，较2025年12月31日增加296.0户，增幅2.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631940555","title":"赛托生物（300583）2026年一季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631940555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631940555?lang=zh_cn&edition=full","pubTime":"2026-04-29 08:59","pubTimestamp":1777424344,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期赛托生物发布2026年一季报。截至本报告期末，公司营业总收入3.28亿元，同比上升26.24%，归母净利润361.66万元，同比上升113.15%。本报告期赛托生物盈利能力上升，毛利率同比增幅146.92%，净利率同比增幅111.34%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900027984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630931167","title":"图解赛托生物年报：第四季度单季净利润同比增长96.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630931167","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630931167?lang=zh_cn&edition=full","pubTime":"2026-04-28 02:10","pubTimestamp":1777313433,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物2025年年报显示，当年度公司主营收入10.17亿元，同比上升4.77%；归母净利润-7314.75万元，同比上升17.6%；扣非净利润-7665.04万元，同比上升25.84%；其中2025年第四季度，公司单季度主营收入2.68亿元，同比上升30.22%；单季度归母净利润-391.72万元，同比上升96.21%；单季度扣非净利润-426.25万元，同比上升96.08%；负债率39.21%，投资收益624.69万元，财务费用3211.44万元，毛利率15.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800005915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625393926","title":"赛托生物（300583）披露回购公司股份进展公告，4月7日股价上涨3.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625393926","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625393926?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:50","pubTimestamp":1775555423,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，赛托生物报收于14.4元，较前一交易日上涨3.15%，最新总市值为27.32亿元。该股当日开盘13.98元，最高14.58元，最低13.9元，成交额达6397.85万元，换手率为2.39%。公司于近日披露《关于回购公司股份的进展公告》。公告显示，山东赛托生物科技股份有限公司于2026年3月6日召开第四届董事会第十三次会议，审议通过回购公司股份方案，拟使用自有资金和自筹资金以集中竞价交易方式回购股份，用于员工持股计划或股权激励。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622608026","title":"赛托生物(300583.SZ)：甲泼尼龙取得化学原料药欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622608026","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622608026?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:49","pubTimestamp":1774428589,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物(300583.SZ)公告，公司控股子公司山东斯瑞药业有限公司(简称“斯瑞药业”)近日收到欧洲药品质量管理局(简称“EDQM”)签发的原料药欧洲药典适用性证书(简称“CEP 证书”)，化学原料药名称为：甲泼尼龙。公告显示，甲泼尼龙是中效、不含卤素皮质激素类药物，用于危重疾病的急救，还可用于内分泌失调、风湿性疾病、胶原性病、皮肤疾病、过敏反应、眼科疾病、胃肠道疾病、血液疾病、白血病、休克、脑水肿、多发性神经炎、脊髓炎及防止癌症化疗引起的呕吐等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619536394","title":"赛托生物最新公告：子公司收到倍他米松化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619536394","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619536394?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:28","pubTimestamp":1773649705,"startTime":"0","endTime":"0","summary":"赛托生物(300583.SZ)公告称，公司控股子公司山东斯瑞药业有限公司收到国家药品监督管理局签发的倍他米松《化学原料药上市申请批准通知书》。倍他米松是一种主要用于治疗过敏和自身免疫性炎症的激素类药物。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600021740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619161447","title":"赛托生物(300583.SZ)子公司收到地塞米松化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619161447","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619161447?lang=zh_cn&edition=full","pubTime":"2026-03-13 15:44","pubTimestamp":1773387871,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物(300583.SZ)发布公告，公司控股子公司山东斯瑞药业有限公司近日收到国家药品监督管理局签发的地塞米松《化学原料药上市申请批准通知书》。地塞米松是一种长效糖皮质激素类药物，具有抗炎、抗过敏、免疫抑制等作用，主要适用于过敏性与自身免疫性炎症性疾病，如结缔组织病，严重的支气管哮喘，皮炎等过敏性疾病，溃疡性结肠炎，急性白血病，恶性淋巴瘤等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛托生物(300583.SZ)子公司收到地塞米松化学原料药上市申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618627232","title":"赛托生物（300583）披露回购股份报告书，3月9日股价下跌0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618627232","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618627232?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:59","pubTimestamp":1773068349,"startTime":"0","endTime":"0","summary":"截至2026年3月9日收盘，赛托生物报收于14.6元，较前一交易日下跌0.14%，最新总市值为27.7亿元。近日，赛托生物披露《回购股份报告书》。公司计划以集中竞价交易方式回购公司股份，用于员工持股计划或股权激励。预计回购股份数量为682,439股至1,364,877股，占公司当前总股本的0.3597%至0.7195%。回购期限为董事会审议通过之日起12个月内。公司已开立回购专用证券账户，董事会已审议通过该方案，无需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900035740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617930685","title":"赛托生物(300583.SZ)拟斥1500万元至3000万元实施回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2617930685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617930685?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:58","pubTimestamp":1772787499,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物(300583.SZ)公告，公司计划以集中竞价交易的方式回购公司股份，回购价格上限不超过21.98元/股(含);回购资金总额不低于1500万元且不超过3000万元。回购股份期限自董事会审议通过本次回购方案之日起12个月内。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613975387","title":"赛托生物（300583）披露关于子公司收到化学原料药欧洲CEP证书的公告，2月24日股价上涨1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613975387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613975387?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:37","pubTimestamp":1771929435,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，赛托生物报收于15.0元，较前一交易日上涨1.01%，最新总市值为28.46亿元。近日，山东赛托生物科技股份有限公司控股子公司山东斯瑞药业有限公司收到欧洲药品质量管理局签发的倍他米松原料药欧洲药典适用性证书，证书编号CEP 2024-446-Rev 00，有效期自2026年2月11日起五年内有效。倍他米松主要用于治疗过敏和自身免疫性炎症，2024年全球需求量近2吨。目前全球有7家倍他米松原料药生产企业持有有效CEP证书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611132885","title":"赛托生物(300583.SZ)取得倍他米松原料药CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2611132885","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611132885?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:36","pubTimestamp":1770971789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物 发布公告，公司控股子公司山东斯瑞药业有限公司近日收到欧洲药品质量管理局签发的原料药欧洲药典适用性证书。涉及化学原料药名称：“BETAMETHASONE 倍他米松”。公司取得倍他米松原料药CEP证书，标志着公司该原料药可以在认可CEP 证书的国际市场进行销售，将为公司倍他米松原料药拓展国际市场带来积极的影响，进一步丰富公司的产品线，有利于提升公司在化学原料药领域的市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609594391","title":"赛托生物（300583）披露控股子公司再次获得高新技术企业证书，2月6日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609594391","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609594391?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:25","pubTimestamp":1770387920,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，赛托生物报收于14.81元，较前一交易日上涨0.14%，最新总市值为28.09亿元。该股当日开盘14.76元，最高14.96元，最低14.7元，成交额达2852.93万元，换手率为1.03%。近日，赛托生物披露《关于控股子公司再次获得高新技术企业证书的公告》。公告显示，公司控股子公司山东斯瑞药业有限公司通过高新技术企业审查，获得编号为GR202537002998的高新技术企业证书，发证时间为2025年12月8日，有效期三年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600041088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608889755","title":"股市必读：赛托生物（300583）预计2025年全年扣非后净利润亏损6600万元至9100万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889755","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889755?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:55","pubTimestamp":1769975709,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，赛托生物报收于14.5元，上涨0.76%，换手率1.7%，成交量3.17万手，成交额4559.83万元。赛托生物发布业绩预告，预计2025年全年归属净利润亏损6300万元至8800万元。公司公告汇总2025年度业绩预告山东赛托生物科技股份有限公司预计2025年度归属于上市公司股东的净利润亏损6,300万元至8,800万元，上年同期亏损8,876.67万元；扣除非经常性损益后的净利润亏损6,600万元至9,100万元，上年同期亏损10,336.12万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607428820","title":"赛托生物（300583）披露2025年度业绩预告，1月30日股价上涨0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607428820","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607428820?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:11","pubTimestamp":1769785870,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，赛托生物报收于14.5元，较前一交易日上涨0.76%，最新总市值为27.51亿元。该股当日开盘14.38元，最高14.58元，最低14.24元，成交额达4559.83万元，换手率为1.7%。公司于近日披露《2025年度业绩预告》。公告显示，山东赛托生物科技股份有限公司预计2025年度归属于上市公司股东的净利润亏损6,300万元至8,800万元，上年同期亏损8,876.67万元；扣除非经常性损益后的净利润亏损6,600万元至9,100万元，上年同期亏损10,336.12万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606922858","title":"股市必读：赛托生物（300583）1月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606922858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606922858?lang=zh_cn&edition=full","pubTime":"2026-01-27 02:22","pubTimestamp":1769451733,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，赛托生物报收于15.24元，上涨2.42%，换手率3.36%，成交量6.25万手，成交额9433.44万元。董秘最新回复投资者： 请问公司25年四季度业绩怎么样？亏损有没有收窄？26年公司经营有什么扭亏为盈的布局吗？2025年度业绩预告披露时间请以公司公告为准。公司将做好生产经营，以业绩回报投资者的信任。交易信息汇总资金流向1月26日主力资金净流入543.51万元；游资资金净流入557.48万元；散户资金净流出1100.99万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700001821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604956681","title":"赛托生物最新公告：收到化学原料药欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2604956681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604956681?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:01","pubTimestamp":1768899718,"startTime":"0","endTime":"0","summary":"赛托生物(300583.SZ)公告称，公司控股子公司斯瑞药业近日收到欧洲药品质量管理局签发的原料药欧洲药典适用性证书。该证书为公司糠酸氟替卡松原料药拓展国际市场带来积极影响，进一步丰富公司产品线，提升市场竞争力。但原料药销售受行业政策和市场需求影响，存在不确定性，投资者需注意相关投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000026060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603994071","title":"赛托生物（300583）披露公司及子公司日常关联交易预计，1月16日股价下跌0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603994071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603994071?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:46","pubTimestamp":1768574771,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，赛托生物报收于14.39元，较前一交易日下跌0.69%，最新总市值为27.3亿元。该股当日开盘14.53元，最高14.62元，最低14.3元，成交额达4224.9万元，换手率为1.57%。近日，赛托生物发布《关于公司及子公司日常关联交易预计的公告》，披露公司预计2026年与关联方天津信谊津津药业有限公司发生日常关联交易，主要为销售商品及提供劳务，预计金额不超过2,000.00万元，截至披露日已发生488.85万元。2025年实际发生金额为5,089.31万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602550614","title":"股市必读：赛托生物（300583）1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602550614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602550614?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:34","pubTimestamp":1768160050,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，赛托生物报收于14.35元，上涨1.06%，换手率1.56%，成交量2.9万手，成交额4128.91万元。董秘最新回复投资者： 请问我们公司在原有的产业领域是否开展了Ai研发？需要指出目前暂无实质性进展，请以公司公告为准，请投资者注意投资风险。交易信息汇总资金流向1月9日主力资金净流出89.5万元；游资资金净流入163.26万元；散户资金净流出73.76万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778740191111,"stockEarnings":[{"period":"1week","weight":0.0138},{"period":"1month","weight":0.0806},{"period":"3month","weight":0.0322},{"period":"6month","weight":-0.0393},{"period":"1year","weight":-0.1857},{"period":"ytd","weight":0.1256}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0637},{"period":"3month","weight":0.0263},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2571},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东赛托生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13671人(较上一季度增加2.21%)","perCapita":"13616股","listingDate":"2017-01-06","address":"山东省菏泽市定陶区东外环路南段","registeredCapital":"18970万元","survey":" 山东赛托生物科技股份有限公司的主营业务是应用基因工程技术和微生物转化技术制造并销售甾体药物原料和中间体。公司的主要产品是甾体核心中间体、高端中间体、呼吸类高端特色原料药、动保类原料药、乳膏鼻喷制剂。","listedPrice":40.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛托生物(300583)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛托生物(300583)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛托生物,300583,赛托生物股票,赛托生物股票老虎,赛托生物股票老虎国际,赛托生物行情,赛托生物股票行情,赛托生物股价,赛托生物股市,赛托生物股票价格,赛托生物股票交易,赛托生物股票购买,赛托生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛托生物(300583)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛托生物(300583)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}